Arrowhead presents preclinical results on ARO-ALK7
ALK7, the company’s investigational RNA interference therapeutic targeting Activin receptor-like kinase 7 being developed as a potential treatment for obesity. The results were presented in a poster ...
Le Lézard1d
Vecima Announces "Turbocharged" DOCSIS® 3.1 Support for Remote MACPHY Nodes
Vecima Networks Inc. announced today its "Turbocharged" DOCSIS 3.1 support for Entra® Remote MACPHY nodes with System Release 24.2.0. Vecima's Entra SC-1D2 and SC-2D Remote MACPHY Nodes enable ...
Le Lézard1d
Beverly Hills MD Launches New YouTube Series "Ancient Beauty Trends" with Hosts Dr. John Layke and Dr. Payman Danielpour
Beverly Hills MD®, the cutting-edge skincare line created by renowned plastic surgeons Dr. John Layke and Dr. Payman ...
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase ...